
    
      The test product (Acetylcysteine 600 mg effervescent tablet) is registered in many EU as well
      as non-EU countries for the secretolytic therapy in acute and chronic bronchopulmonary
      diseases.

      The primary aim of this trial is to assess the efficacy of three different total daily doses
      of the investigational product containing 600 mg acetylcysteine per effervescent tablet
      compared to placebo for the treatment of acute uncomplicated rhinosinusitis.

      The trial design was chosen according to the recommendation of the current guidelines
      EMA/CHMP/ICH/135/19953 and CPMP/ICH/291/95
    
  